Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts

Blood, Vol. 104, Issue 2, 307-313, July 15, 2004
This Article
Right arrow Abstract
Right arrow Full Text
Services
Right arrow Email this article to a friend
Right arrow Alert me to new issues of the journal
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via CrossRef

Genetic evidence for lineage-related and differentiation stage–related contribution of somatic PTPN11 mutations to leukemogenesis in childhood acute leukemia
Blood Tartaglia et al. 104: 307

Supplemental materials for: Tartaglia et al, Vol 104, Issue 2, 307-313

Files in this Data Supplement:

  • Table S1. Main biologic features of the ALL cohort included in the study (PDF file, 256 KB)
  • Table S2. NRAS and KRAS2 mutations in childhood acute leukemia (PDF file, 180 KB)
  • Figure S1. Distribution of PTPN11 and RAS mutations and TEL-AML1 fusion gene by DNA content and age at diagnosis in children with B-cell precursor ALL (JPEG file, 65 KB) - Figure S1. Distribution of PTPN11 and RAS mutations and TEL-AML1 fusion gene by DNA content and age at diagnosis in children with B-cell precursor ALL (JPEG file, 65 KB): (A) DNA content. PTPN11 and NRAS/KRAS2 gene mutations show a significant higher prevalence among children with hyperdiploid DNA content compared with those with DNA Index lower than or equal to 1 (PTPN11: 14% vs 4%, Pearson 2 = 9.97, P = .002; RAS genes: 35% vs 19%, Pearson 2 = 7.84, P = .005), whereas TEL-AML1 gene rearrangements are almost exclusively associated with diploid DNA content (3% vs 33%, Pearson 2 = 29.78, P < .001). White bars indicate DNA Index less than or equal to 1; solid bars indicate DNA Index greater than 1. (B) Age at diagnosis. Prevalence of PTPN11 mutations is significantly higher among children with age at diagnosis greater than or equal to 15 years compared with the other classes (P = .022, Fisher exact test), whereas prevalence of the TEL-AML1 fusion gene is restricted to children younger than 15 years, with highest recurrence among children between 5 and 10 years old (P = .005, Fisher exact test). No association between age at diagnosis and prevalence of RAS gene mutations is observed (P = 0.819, Fisher exact test). Age at diagnosis (in years) is: white bars, < 5; light gray bars, ≥ 5 and < 10; dark gray bars, ≥ 10 and < 15; and solid bars, ≥ 15.




This Article
Right arrow Abstract
Right arrow Full Text
Services
Right arrow Email this article to a friend
Right arrow Alert me to new issues of the journal
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via CrossRef

 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2009 by American Society of Hematology         Online ISSN: 1528-0020